The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Resveratrol inhibits phorbol ester-induced expression of COX-2 and activation of NF-κB in mouse skin by blocking IκB kinase activity
Open accessAbstract
Aberrant expression of cyclooxygenase-2 (COX-2) has been implicated in tumor promotion. Resveratrol, a phytoalexin present in grapes, was reported to inhibit multistage mouse skin carcinogenesis. In the present study, we found that topically applied resveratrol significantly inhibited COX-2 expression induced by the tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA). Resveratrol-suppressed phosphorylation and subsequent degradation of IkappaBalpha, thereby inhibiting activation of nuclear factor-kappaB (NF-kappaB) in TPA-stimulated mouse skin. Pretreatment with resveratrol also suppressed TPA-induced phosphorylation of extracellular signal-regulated protein kinase (ERK) and p38 mitogen-activated protein (MAP) kinase. Resveratrol blunted TPA-induced phosphorylation of p65 and its interaction with CBP/p300, rendering NF-kappaB transcriptionally inactive. To get further insights into the molecular basis of NF-kappaB inactivation by resveratrol, we examined the role of IkappaB kinase (IKK) in mediating TPA-induced activation of NF-kappaB and COX-2 expression. TPA treatment led to rapid induction of IKK activity in mouse skin, which was abolished either by resveratrol or an IKK inhibitor Bay 11-7082. Topical application of Bay 11-7082 also abrogated TPA-induced NF-kappaB activation and COX-2 expression, supporting the involvement of IKK in TPA-induced COX-2 expression. Taken together, the above findings suggest that resveratrol targets IKK in blocking TPA-induced NF-kappaB activation and COX-2 expression in mouse skin in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Regulation of Cyclooxgenase-2 mRNA Stability by Taxanes
Subbaramaiah, K., Marmo, T. P., Dixon, D. A., & Dannenberg, A. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301481200 · Cited by 195
RetractedTHE NF-κB AND IκB PROTEINS: New Discoveries and Insights
Baldwin, A. S. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.649 · Cited by 4,979
Cancer chemopreventive activity of resveratrol, a natural product derived from grapes
Jang, M., Cai, L., Udeani, G. O., Slowing, K. V., Thomas, C. F., Beecher, C. W. W., Fong, H. H. S., Farnsworth, N. R., Kinghorn, A. D., Mehta, R. G., et al. (1997) · Science · doi:10.1126/science.275.5297.218 · Cited by 4,935
Missing Pieces in the NF-κB Puzzle
Ghosh, S., & Karin, M. (2002) · Cell · doi:10.1016/s0092-8674(02)00703-1 · Cited by 3,638
Cancer chemoprevention with dietary phytochemicals
Surh, Y.-J. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1189 · Cited by 2,955
Self-citationIKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer
Greten, F. R., Eckmann, L., Greten, T. F., Park, J. M., Li, Z.-W., Egan, L. J., Kagnoff, M. F., & Karin, M. (2004) · Cell · doi:10.1016/j.cell.2004.07.013 · Cited by 2,433
NF-κB functions as a tumour promoter in inflammation-associated cancer
Pikarsky, E., Porat, R. M., Stein, I., Abramovitch, R., Amit, S., Kasem, S., Gutkovich-Pyest, E., Urieli-Shoval, S., Galun, E., & Ben-Neriah, Y. (2004) · Nature · doi:10.1038/nature02924 · Cited by 2,430
Aggarwal, B. B. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.003 · Cited by 1,574
The role of cyclooxygenases in inflammation, cancer, and development
Williams, C. S., Mann, M., & DuBois, R. N. (1999) · Oncogene · doi:10.1038/sj.onc.1203286 · Cited by 1,417
Zhong, H., Voll, R. E., & Ghosh, S. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80066-0 · Cited by 1,210
How NF-κB is activated: the role of the IκB kinase (IKK) complex
Karin, M. (1999) · Oncogene · doi:10.1038/sj.onc.1203219 · Cited by 1,156
Manna, S. K., Mukhopadhyay, A., & Aggarwal, B. B. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.12.6509 · Cited by 879
IκB Kinases Phosphorylate NF-κB p65 Subunit on Serine 536 in the Transactivation Domain
Sakurai, H., Chiba, H., Miyoshi, H., Sugita, T., & Toriumi, W. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.43.30353 · Cited by 823
CREB-binding protein/p300 are transcriptional coactivators of p65
Gerritsen, M. E., Williams, A. J., Neish, A. S., Moore, S., Shi, Y., & Collins, T. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.7.2927 · Cited by 816
Madrid, L. V., Mayo, M. W., Reuther, J. Y., & Baldwin, A. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101103200 · Cited by 777
p38-dependent marking of inflammatory genes for increased NF-κB recruitment
Saccani, S., Pantano, S., & Natoli, G. (2002) · Nature Immunology · doi:10.1038/ni748 · Cited by 693
Bharti, A. C., Donato, N., Singh, S., & Aggarwal, B. B. (2003) · Blood · doi:10.1182/blood-2002-05-1320 · Cited by 685
Cyclooxygenase 2: a molecular target for cancer prevention and treatment
Subbaramaiah, K., & Dannenberg, A. J. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(02)00043-3 · Cited by 649
Balkwill, F., & Coussens, L. M. (2004) · Nature · doi:10.1038/431405a · Cited by 627
Tsai, S., Lin‐Shiau, S., & Lin, J. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702357 · Cited by 511
Activation of the Protein Kinase ERK5/BMK1 by Receptor Tyrosine Kinases
Kamakura, S., Moriguchi, T., & Nishida, E. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.37.26563 · Cited by 510
Holmes-McNary, M. Q., & Baldwin, A. S. (2000) · PubMed · doi:10.17615/wdcc-wb89 · Cited by 498
At the Crossroads of Inflammation and Cancer
Clevers, H. (2004) · Cell · doi:10.1016/j.cell.2004.09.005 · Cited by 493
Many actions of cyclooxygenase‐2 in cellular dynamics and in cancer
Cao, Y., & Prescott, S. M. (2002) · Journal of Cellular Physiology · doi:10.1002/jcp.10068 · Cited by 464
Banerjee, S., Bueso-Ramos, C., & Aggarwal, B. B. (2002) · PubMed · Cited by 423
The IKK/NF-κB activation pathway—a target for prevention and treatment of cancer
Greten, F. (2004) · Cancer Letters · doi:10.1016/j.canlet.2003.08.029 · Cited by 410
Chun, K.-S., & Surh, Y.-J. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.05.031 · Cited by 402
Self-citationYang, F., Tang, E., Guan, K., & Wang, C.-Y. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.11.5630 · Cited by 392
Sizemore, N., Lerner, N., Dombrowski, N., Sakurai, H., & Stark, G. R. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m110572200 · Cited by 390
Rel/NF-κB and IκB proteins: an overview
May, M. J., & Ghosh, S. (1997) · Seminars in Cancer Biology · doi:10.1006/scbi.1997.0057 · Cited by 378
Tiano, H. F., Loftin, C. D., Akunda, J., Lee, C. A., Spalding, J. W., Sessoms, A. R., Dunson, D. B., Rogan, E. G., Morham, S. G., Smart, R. C., et al. (2002) · PubMed · Cited by 344
Wilms, H., Rosenstiel, P., Sievers, J., Deuschl, G., Zecca, L., & Lucius, R. (2003) · The FASEB Journal · doi:10.1096/fj.02-0314fje · Cited by 337
Takada, Y., Bhardwaj, A., Potdar, P., & Aggarwal, B. B. (2004) · Oncogene · doi:10.1038/sj.onc.1208169 · Cited by 310
Chun, K.-S. (2003) · Carcinogenesis · doi:10.1093/carcin/bgg107 · Cited by 296
Kim, S. O., Kundu, J. K., Shin, Y. K., Park, J.-H., Cho, M.-H., Kim, T.-Y., & Surh, Y.-J. (2005) · Oncogene · doi:10.1038/sj.onc.1208446 · Cited by 295
Self-citationDexamethasone Destabilizes Cyclooxygenase 2 mRNA by Inhibiting Mitogen-Activated Protein Kinase p38
Lasa, M., Brook, M., Saklatvala, J., & Clark, A. R. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.3.771-780.2001 · Cited by 259
Effects of MAP kinase cascade inhibitors on the MKK5/ERK5 pathway
Mody, N., Leitch, J., Armstrong, C., Dixon, J., & Cohen, P. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02651-5 · Cited by 250
Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis
Müller-Decker, K., Neufang, G., Berger, I., Neumann, M., Marks, F., & Fürstenberger, G. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192323799 · Cited by 240
Chemoprevention of skin cancer by grape constituent resveratrol: relevance to human disease?
Aziz, M. H., Reagan‐Shaw, S., Wu, J., Longley, B. J., & Ahmad, N. (2005) · The FASEB Journal · doi:10.1096/fj.04-3582fje · Cited by 220
Molecular basis of chemoprevention by resveratrol: NF-κB and AP-1 as potential targets
Kundu, J. K., & Surh, Y.-J. (2004) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2004.05.019 · Cited by 212
Self-citationTranscriptional Regulation of Cyclooxygenase-2 in Mouse Skin Carcinoma Cells
Kim, Y., & Fischer, S. M. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.42.27686 · Cited by 197
Inhibition of the NF‐κB transcriptional activity by protein kinase A
Takahashi, N., Tetsuka, T., Uranishi, H., & Okamoto, T. (2002) · European Journal of Biochemistry · doi:10.1046/j.1432-1033.2002.03157.x · Cited by 170
Role of the BMK1/ERK5 signaling pathway: lessons from knockout mice
Hayashi, M., & Lee, J.-D. (2004) · Journal of Molecular Medicine · doi:10.1007/s00109-004-0602-8 · Cited by 169
Transcription: Gene control by targeted histone acetylation
Imhof, A., & Wolffe, A. P. (1998) · Current Biology · doi:10.1016/s0960-9822(98)70268-4 · Cited by 155
The Role of CBP in Estrogen Receptor Cross-Talk with Nuclear Factor- B in HepG2 Cells
Harnish, D. C., Scicchitano, M. S., Adelman, S. J., Lyttle, C. R., & Karathanasis, S. K. (2000) · Endocrinology · doi:10.1210/endo.141.9.7646 · Cited by 148
Kundu, J. K., Na, H.-K., Chun, K., Kim, Y. K., Lee, S. J., Lee, S. S., Lee, O.-S., Sim, Y.-C., & Surh, Y. (2003) · Journal of Nutrition · doi:10.1093/jn/133.11.3805s · Cited by 146
Self-citationMohan, S., & Epstein, J. B. (2003) · Oral Oncology · doi:10.1016/s1368-8375(03)00035-6 · Cited by 127
Chun, K. (2003) · Carcinogenesis · doi:10.1093/carcin/bgh076 · Cited by 121
Wu, D., Marko, M. G., Claycombe, K., Paulson, K. E., & Meydani, S. N. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m207470200 · Cited by 109
Dai, Y., Pei, X., Rahmani, M., Conrad, D. H., Dent, P., & Grant, S. (2003) · Blood · doi:10.1182/blood-2003-09-3037 · Cited by 107
Lappas, M., Yee, K., Permezel, M., & Rice, G. E. (2004) · Endocrinology · doi:10.1210/en.2004-0809 · Cited by 102
Ethanol-induced iNOS and COX-2 expression in cultured astrocytes via NF-κB
Blanco, A. M. A., Pascual, M., Vallés, S. L., & Guerri, C. (2004) · Neuroreport · doi:10.1097/00001756-200403220-00021 · Cited by 102
Guo, Y.-S., Cheng, J.-Z., Jin, G., Gutkind, J. S., Hellmich, M. R., & Townsend, C. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m209016200 · Cited by 97
Kundu, J. K., Mossanda, K. S., Na, H.-K., & Surh, Y. (2004) · Cancer Letters · doi:10.1016/j.canlet.2004.07.029 · Cited by 93
Self-citationKumagai, T., Nakamura, Y., Osawa, T., & Uchida, K. (2002) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.2001.2601 · Cited by 52
Asou, H., Koshizuka, K., Kyo, T., Takata, N., Kamada, N., & Koeffler, H. P. (2002) · International Journal of Hematology · doi:10.1007/bf02982118 · Cited by 42
Mifflin, R. C., Saada, J. I., Mari, J. F. D., Valentich, J. D., Adegboyega, P. A., & Powell, D. W. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.2.470 · Cited by 34
(1998) · doi:10.1002/(sici)1521-1878(199808)20:8<615::aid-bies4>3.0.co;2-h
Cited by
Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets
Wang, B., Wu, L., Chen, J., Dong, L., Chen, C., Wen, Z., Hu, J., Fleming, I., & Wang, D. W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00443-w · Cited by 1,414
The therapeutic potential of resveratrol: a review of clinical trials
Berman, A. Y., Motechin, R. A., Wiesenfeld, M. Y., & Holz, M. K. (2017) · npj Precision Oncology · doi:10.1038/s41698-017-0038-6 · Cited by 888
Anti-Inflammatory Action and Mechanisms of Resveratrol
Meng, T., Xiao, D., Muhammed, A., Deng, J., Chen, L., & He, J. (2021) · Molecules · doi:10.3390/molecules26010229 · Cited by 698
Resveratrol (RV): A pharmacological review and call for further research
Zhang, L.-X., Li, C.-X., Kakar, M. U., Khan, M. S., Wu, P.-F., Amir, R. M., Dai, D.-F., Naveed, M., Li, Q.-Y., Saeed, M., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112164 · Cited by 546
Targeting NOX, iNOS and COX-2 in inflammatory cells: chemoprevention using food phytochemicals
Murakami, A., & Ohigashi, H. (2007) · International Journal of Cancer · doi:10.1002/ijc.23161 · Cited by 478
Metadata
- Authors
- Kundu, J. K., Shin, Y. K., Kim, S. H., & Surh, Y.-J.
- Venue
- Carcinogenesis
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-02-12
- Volume
- 27
- Issue
- 7
- Pages
- 1465-1474
- ISSN
- 0143-3334 (ISSN-L)
- 1460-2180
- OpenAlex
- W2165844588
- Cited by
- 271
- References
- 59
- FWCI
- 8.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.